Anacor Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Anacor Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013092
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Anacor Pharmaceuticals Inc (Anacor) is a biopharmaceutical company that discovers, develops and markets small molecule therapeutics based on its boron chemistry platform. The company’s marketed products include a topical solution which is an oxaborole antifungal that is used for the topical treatment of onychomycosis of the toenails. Its lead pipeline candidates encompass a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor for the treatment of mild-to-moderate atopic dermatitis and psoriasis; and an antibiotic for the potential treatment of infections caused from gram-negative bacteria. Anacor’s boron chemistry platform is used to treat diseases in animals caused due to bacteria, fungi and parasites. It out-licensed three investigational compounds: indication targeted at the treatment of an animal health to Eli Lilly and Company; indication for the treatment of human African trypanosomiasis to Drugs for Neglected Diseases; and indication targeted at the treatment of tuberculosis to GlaxoSmithKline LLC. Anacor is headquartered in Palo Alto, California, the US.

Anacor Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Anacor Pharma Amends Co-Marketing Agreement with Sandoz for Kerydin 10
Anacor Pharma Ammends its Research Agreement With Bill & Melinda Gates Foundation 12
Anacor Pharma Amends And Expands Research Collaboration With GlaxoSmithKline 13
Anacor Pharma And Medicines For Malaria Venture Extend Co-Development Agreement For AN3661 15
iOWH Enters Into Research Agreement With Anacor Pharma 16
Anacor Pharma Enters Into Research And Development Agreement With Medicis Pharma 17
Equity Offering 18
Anacor Pharma Files Registration Statement For Public Offering Of Securities For Up To US$50 Million 18
Anacor Pharma Completes Public Offering Of Common Stock For US$23 Million 19
Anacor Pharma Completes Public Offering Of Common Stock For US$24 Million 20
Anacor Pharma Completes Public Offering Of Common Stock For US$21.5 Million 21
Debt Offering 23
Anacor Pharma Raises USD287.5 Million in Private Placement of 2% Notes Due 2023 23
Anacor Pharma Raises USD82.5 Million Private Placement of Notes Due 2021 25
Anacor Pharma Raises USD8 Million in Private Placement of Notes Due 2021 27
Acquisition 29
Pfizer Acquires Anacor Pharma for USD5.2 Billion 29
Anacor Pharmaceuticals Inc – Key Competitors 31
Anacor Pharmaceuticals Inc – Key Employees 32
Anacor Pharmaceuticals Inc – Locations And Subsidiaries 33
Head Office 33
Recent Developments 34
Financial Announcements 34
May 10, 2016: Anacor Pharmaceuticals Reports First Quarter 2016 Financial Results 34
Feb 29, 2016: Anacor Pharmaceuticals Reports 2015 Fourth Quarter and Year-End Financial Results 36
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Anacor Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Anacor Pharma Amends Co-Marketing Agreement with Sandoz for Kerydin 10
Anacor Pharma Ammends its Research Agreement With Bill & Melinda Gates Foundation 12
Anacor Pharma Amends And Expands Research Collaboration With GlaxoSmithKline 13
Anacor Pharma And Medicines For Malaria Venture Extend Co-Development Agreement For AN3661 15
iOWH Enters Into Research Agreement With Anacor Pharma 16
Anacor Pharma Enters Into Research And Development Agreement With Medicis Pharma 17
Anacor Pharma Files Registration Statement For Public Offering Of Securities For Up To US$50 Million 18
Anacor Pharma Completes Public Offering Of Common Stock For US$23 Million 19
Anacor Pharma Completes Public Offering Of Common Stock For US$24 Million 20
Anacor Pharma Completes Public Offering Of Common Stock For US$21.5 Million 21
Anacor Pharma Raises USD287.5 Million in Private Placement of 2% Notes Due 2023 23
Anacor Pharma Raises USD82.5 Million Private Placement of Notes Due 2021 25
Anacor Pharma Raises USD8 Million in Private Placement of Notes Due 2021 27
Pfizer Acquires Anacor Pharma for USD5.2 Billion 29
Anacor Pharmaceuticals Inc, Key Competitors 31
Anacor Pharmaceuticals Inc, Key Employees 32

★海外企業調査レポート[Anacor Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • BMG Resources Ltd (BMG):企業の財務・戦略的SWOT分析
    Summary BMG Resources Ltd (BMG), formerly known as Brazilian Metals Group Ltd, is a mineral exploration company that explores lithium brine in Chile. The company's portfolio includes exploration tenements located in the Republic of Cyprus. Its product portfolio include nickel, gold, copper, cobalt, …
  • Mesa Laboratories Inc (MLAB)-医療機器分野:企業M&A・提携分析
    Summary Mesa Laboratories Inc (Mesa) is a medical device company that manufactures and markets validation and monitoring instruments. The company’s products comprise mesa biological indicators, DryCal gas flow calibrators, BGI ambient particulate sampling, DialyGuard dialysate meters, SureTorque cap …
  • The Royal Bank of Scotland Group Plc:企業のM&A・事業提携・投資動向
    The Royal Bank of Scotland Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Royal Bank of Scotland Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports …
  • Laboratorios Farmaceuticos Rovi SA (ROVI):企業の財務・戦略的SWOT分析
    Summary Laboratorios Farmaceuticos Rovi SA (Rovi) is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of prescription and hospital products. The company's product portfolio includes licensed prescription pharmaceuticals in the therapeutic areas of cardiovas …
  • Noel Gifts International Ltd. (543):企業の財務・戦略的SWOT分析
    Noel Gifts International Ltd. (543) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Northbridge Financial Corporation:企業の戦略的SWOT分析
    Northbridge Financial Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Hospitality Properties Trust:企業のM&A・事業提携・投資動向
    Hospitality Properties Trust - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hospitality Properties Trust Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • RayBiotech Inc-製薬・医療分野:企業M&A・提携分析
    Summary RayBiotech Inc (RayBiotech) is a life science company that offers proteins, antibodies and immunological kits. The company’s products include antibody arrays, elisa, functional assays, antibodies and custom recombinant protein service. It provides services such as testing services, custom se …
  • Uniper SE (UN01):企業の財務・戦略的SWOT分析
    Uniper SE (UN01) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Ascendant Group Limited (AGL.BH):企業の戦略的SWOT分析
    Ascendant Group Limited (AGL.BH) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Dunmore Corporation:企業の戦略的SWOT分析
    Dunmore Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Acciona SA (ANA):電力:M&Aディール及び事業提携情報
    Summary Acciona SA (Acciona) is a provider of sustainable solutions for infrastructure and renewable energy projects. The company develops and manages infrastructure, renewable energy, water, and other facilities. Its operations cover the whole value chain, from design and construction to operation …
  • Tata Communications Ltd (TATACOMM):企業の財務・戦略的SWOT分析
    Tata Communications Ltd (TATACOMM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Ambry Genetics Corp-製薬・医療分野:企業M&A・提携分析
    Summary Ambry Genetics Corp (Ambry Genetics) is a biotechnology company that offers genetic testing services. The company offers clinical diagnostics services, which include tests, forms, billing, managed care, order kits, reporting, licenses, family studies program, variant classification and secur …
  • Constantia Industries AG:企業の戦略的SWOT分析
    Constantia Industries AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Flex Ltd (FLEX)-エネルギー分野:企業M&A・提携分析
    Summary Flex Ltd (Flex) formerly Flextronics International Ltd is a provider of technology solutions. It designs, manufactures and provides supply chain services to original equipment manufacturers. The company’s major solutions include disposables, drug delivery, diagnostics devices, automotive ele …
  • Tokmanni Group Oyj (TOKMAN):企業の財務・戦略的SWOT分析
    Tokmanni Group Oyj (TOKMAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Centrais Eletricas Brasileiras S.A.:企業の戦略・SWOT・財務情報
    Centrais Eletricas Brasileiras S.A. - Strategy, SWOT and Corporate Finance Report Summary Centrais Eletricas Brasileiras S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Minnesota Municipal Power Agency:企業の戦略的SWOT分析
    Minnesota Municipal Power Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Delegat’s Group Limited:企業の戦略・SWOT・財務分析
    Delegat's Group Limited - Strategy, SWOT and Corporate Finance Report Summary Delegat's Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆